At 19.7x earnings and just 10.8x forward earnings, the market is clearly discounting near-term deterioration despite the stock sitting on a solid Altman Z-Score of 3.2, which signals low bankruptcy risk. A forward multiple nearly half the trailing P/E implies either a steep earnings reset already priced in or skepticism around sustainability. With a modest 1.4x book and 2.6x sales, this is not an expensive large-cap healthcare name, especially given its $25,384M market cap. The market appears cautious rather than euphoric, and the balance sheet strength suggests the downside may be more sentiment-driven than solvency-driven.